About cardiol therapeutics inc - CRDL
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the "ARCHER" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
CRDL At a Glance
Cardiol Therapeutics, Inc.
2265 Upper Middle Road East
Oakville, Ontario L6H 0G5
| Phone | 1-289-910-0850 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -24,203,213.87 | |
| Sector | Health Technology | Employees | 23 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CRDL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 7.346 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.761 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
CRDL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,052,313.647 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CRDL Liquidity
| Current Ratio | 4.156 |
| Quick Ratio | 4.156 |
| Cash Ratio | 3.787 |
CRDL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -122.90 |
| Return on Equity | -160.094 |
| Return on Total Capital | -184.281 |
| Return on Invested Capital | -159.299 |
CRDL Capital Structure
| Total Debt to Total Equity | 0.702 |
| Total Debt to Total Capital | 0.697 |
| Total Debt to Total Assets | 0.531 |
| Long-Term Debt to Equity | 0.488 |
| Long-Term Debt to Total Capital | 0.484 |